About: Oxilorphan

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Oxilorphan (INN, USAN) (developmental code name L-BC-2605) is an opioid antagonist of the morphinan family that was never marketed. It acts as a μ-opioid receptor (MOR) antagonist but a κ-opioid receptor (KOR) partial agonist, and has similar effects to naloxone and around the same potency as an MOR antagonist. Oxilorphan has some weak partial agonist actions at the MOR (with miosis, nausea, dizziness, and some euphoria observed) and can produce hallucinogenic/dissociative effects at sufficient doses, indicative of KOR activation. It was trialed for the treatment of opioid addiction, but was not developed commercially. The KOR agonist effects of oxilorphan are associated with dysphoria, which combined with its hallucinogenic effects, serve to limit its clinical usefulness; indeed, many pat

thumbnail
Property Value
dbo:abstract
  • Oxilorphan (INN, USAN) (developmental code name L-BC-2605) is an opioid antagonist of the morphinan family that was never marketed. It acts as a μ-opioid receptor (MOR) antagonist but a κ-opioid receptor (KOR) partial agonist, and has similar effects to naloxone and around the same potency as an MOR antagonist. Oxilorphan has some weak partial agonist actions at the MOR (with miosis, nausea, dizziness, and some euphoria observed) and can produce hallucinogenic/dissociative effects at sufficient doses, indicative of KOR activation. It was trialed for the treatment of opioid addiction, but was not developed commercially. The KOR agonist effects of oxilorphan are associated with dysphoria, which combined with its hallucinogenic effects, serve to limit its clinical usefulness; indeed, many patients who experienced these side effects refused to take additional doses in clinical trials. (en)
dbo:casNumber
  • 42281-59-4
dbo:fdaUniiCode
  • 9Y9J2J74TO
dbo:kegg
  • D05299
dbo:pubchem
  • 5361090
dbo:thumbnail
dbo:wikiPageID
  • 13967449 (xsd:integer)
dbo:wikiPageLength
  • 5130 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 1051579244 (xsd:integer)
dbo:wikiPageWikiLink
dbp:atcPrefix
  • None (en)
dbp:c
  • 20 (xsd:integer)
dbp:casNumber
  • 42281 (xsd:integer)
dbp:chemspiderid
  • 16736680 (xsd:integer)
dbp:h
  • 27 (xsd:integer)
dbp:iupacName
  • -17 (xsd:integer)
dbp:kegg
  • D05299 (en)
dbp:n
  • 1 (xsd:integer)
dbp:o
  • 2 (xsd:integer)
dbp:pubchem
  • 5361090 (xsd:integer)
dbp:smiles
  • Oc3ccc4C[C@H]1NCC5CC5 (en)
dbp:stdinchi
  • 1 (xsd:integer)
dbp:stdinchikey
  • STBZIDOIKQNFCQ-HSALFYBXSA-N (en)
dbp:unii
  • 9 (xsd:integer)
dbp:verifiedrevid
  • 447991507 (xsd:integer)
dbp:watchedfields
  • changed (en)
dbp:width
  • 140 (xsd:integer)
dbp:wikiPageUsesTemplate
dcterms:subject
gold:hypernym
rdf:type
rdfs:comment
  • Oxilorphan (INN, USAN) (developmental code name L-BC-2605) is an opioid antagonist of the morphinan family that was never marketed. It acts as a μ-opioid receptor (MOR) antagonist but a κ-opioid receptor (KOR) partial agonist, and has similar effects to naloxone and around the same potency as an MOR antagonist. Oxilorphan has some weak partial agonist actions at the MOR (with miosis, nausea, dizziness, and some euphoria observed) and can produce hallucinogenic/dissociative effects at sufficient doses, indicative of KOR activation. It was trialed for the treatment of opioid addiction, but was not developed commercially. The KOR agonist effects of oxilorphan are associated with dysphoria, which combined with its hallucinogenic effects, serve to limit its clinical usefulness; indeed, many pat (en)
rdfs:label
  • Oxilorphan (en)
owl:sameAs
prov:wasDerivedFrom
foaf:depiction
foaf:isPrimaryTopicOf
is dbo:wikiPageWikiLink of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License